Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
作者信息
Vidyasagar Nitin, Bunting Samuel R, Arora Vineet M, Ari Mim
机构信息
Pritzker School of Medicine, The University of Chicago, Chicago, Illinois.
Department of Psychiatry & Behavioral Neuroscience, The University of Chicago, Chicago, Illinois.
出版信息
JAMA. 2024 Feb 13;331(6):524-526. doi: 10.1001/jama.2023.26522.
Abstract
摘要
相似文献
1
Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
JAMA. 2024 Feb 13;331(6):524-526. doi: 10.1001/jama.2023.26522.
2
3
Predictors of availability of long-acting medication for opioid use disorder.
Drug Alcohol Depend. 2019 Nov 1;204:107586. doi: 10.1016/j.drugalcdep.2019.107586. Epub 2019 Sep 25.
4
Early Long-Acting Buprenorphine for Opioid Use Disorder in the Setting of Acute Pain.
J Addict Med. 2024;18(5):608-609. doi: 10.1097/ADM.0000000000001333. Epub 2024 May 31.
5
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3.
6
Buprenorphine Treatment for Opioid Use Disorder: An Overview.
CNS Drugs. 2019 Jun;33(6):567-580. doi: 10.1007/s40263-019-00637-z.
7
Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
Addiction. 2017 Mar;112(3):386-387. doi: 10.1111/add.13539. Epub 2016 Aug 26.
8
Managing emergency department patients with opioid use disorder.
Emerg Med Pract. 2024 Jun 1;26(6):1-24. Print 2024 Jun.
9
Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Subst Abus. 2015;36(2):226-31. doi: 10.1080/08897077.2015.1010031. Epub 2015 Mar 16.
10
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
Drug Alcohol Depend. 2019 Jul 1;200:34-39. doi: 10.1016/j.drugalcdep.2019.02.031. Epub 2019 May 3.
引用本文的文献
1
Opioid and alcohol use disorder medication availability in outpatient care: national estimates & potential policy levers.
Health Aff Sch. 2025 Apr 9;3(4):qxaf040. doi: 10.1093/haschl/qxaf040. eCollection 2025 Apr.
2
Factors predicting access to medications for opioid use disorder for housed and unhoused patients: A machine learning approach.
PLoS One. 2024 Sep 27;19(9):e0308791. doi: 10.1371/journal.pone.0308791. eCollection 2024.
3
Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022.
Addiction. 2024 Dec;119(12):2211-2215. doi: 10.1111/add.16652. Epub 2024 Aug 16.
Zotero 插件